Gastroesophageal Adenocarcinoma Terminated Phase 2 Trials for Panitumumab (DB01269)

IndicationStatusPhase
DBCOND0030813 (Gastroesophageal Adenocarcinoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01182610Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal AdenocarcinomaTreatment